Patents Assigned to Genentech
  • Publication number: 20100015135
    Abstract: The invention provides anti-EphB4 antibodies, and compositions comprising and methods of using these antibodies.
    Type: Application
    Filed: January 4, 2007
    Publication date: January 21, 2010
    Applicant: Genentech, Inc.
    Inventors: Yan Wu, Minhong Yan
  • Publication number: 20100015157
    Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
    Type: Application
    Filed: September 4, 2009
    Publication date: January 21, 2010
    Applicant: Genentech, Inc.
    Inventors: James Andya, Shiang C. Gwee, Jun Liu, Ye Shen
  • Publication number: 20100016556
    Abstract: Variant immunoglobulins, particularly humanized antibody polypeptides are provided, along with methods for their preparation and use. Consensus immunoglobulin sequences and structural models are also provided.
    Type: Application
    Filed: January 4, 2008
    Publication date: January 21, 2010
    Applicant: Genentech, Inc.
    Inventors: PAUL J. CARTER, Leonard G. Presta
  • Patent number: 7649082
    Abstract: A novel growth factor, persephin, which belongs to the GDNF/neurturin family of growth factors, is disclosed. The human, mouse and rat amino acid sequences have been identified. Human, mouse and rat persephin genomic DNA sequences have been cloned and sequenced and the respective cDNA sequences identified. In addition, methods for treating degenerative conditions using persephin, methods for detecting persephin gene alterations and methods for detecting and monitoring patient levels of persephin are provided. Methods for identifying additional members of the persephin-neurturin-GDNF family of growth factors are also provided.
    Type: Grant
    Filed: January 18, 2005
    Date of Patent: January 19, 2010
    Assignees: Washington University, Genentech, Inc.
    Inventors: Eugene M. Johnson, Jeffrey D. Milbrandt, Paul T. Kotzbauer, Patricia A. Lampe, Robert D. Klein, Frederic J. de Sauvage
  • Publication number: 20100010195
    Abstract: The present invention is directed to novel polypeptides having homology to members of the tumor necrosis factor receptor family and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: April 8, 2009
    Publication date: January 14, 2010
    Applicant: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Audrey Goddard, Austin Gurney, Scot A. Marsters, Robert M. Pitti, William I. Wood
  • Publication number: 20100003252
    Abstract: The present application describes methods for blocking immune response to foreign antigens in a mammal using antagonists which bind to CD20.
    Type: Application
    Filed: September 8, 2009
    Publication date: January 7, 2010
    Applicants: Genentech, Inc., Biogen Idec Inc.
    Inventors: Antonio J. Grillo-Lopez, Lori A. Kunkel, Mark D. Pescovitz
  • Publication number: 20100003766
    Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)p??I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
    Type: Application
    Filed: April 21, 2009
    Publication date: January 7, 2010
    Applicant: GENENTECH, INC.
    Inventors: CHARLES W. EIGENBROT, JAGATH REDDY JUNUTULA, HENRY LOWMAN, HELGA E. RAAB, RICHARD VANDLEN
  • Publication number: 20100003239
    Abstract: The invention relates to anti-hedgehog antibodies, their use in the detection of hedgehog expression in tissue, and to the use of such detection in the treatment of cancer.
    Type: Application
    Filed: December 22, 2008
    Publication date: January 7, 2010
    Applicant: Genentech, Inc.
    Inventor: Suzanna J. Scales
  • Publication number: 20100004269
    Abstract: The invention relates to imidazopyridines of formula I with anti-cancer and/or anti-inflammatory activity and more specifically to imidazopyridines which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Application
    Filed: April 29, 2009
    Publication date: January 7, 2010
    Applicant: Genentech, Inc.
    Inventors: Stephen Price, Robert Heald, Wendy Lee, Mark E. Zak, Joanne Frances Mary Hewitt
  • Patent number: 7642242
    Abstract: The present invention is directed to novel polypeptides having sequence similarity to GDNFR and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: February 20, 2007
    Date of Patent: January 5, 2010
    Assignee: Genentech, Inc.
    Inventors: J. Christopher Grimaldi, Somasekar Seshagiri, Jeremy Stinson, William I. Wood, Zemin Zhang
  • Patent number: 7642228
    Abstract: The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heteromultimer formation and hinder homomultimer formation. “Protuberances” are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine).
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: January 5, 2010
    Assignee: Genentech, Inc.
    Inventors: Paul J. Carter, Leonard G. Presta, John B. Ridgway
  • Publication number: 20090325962
    Abstract: The compounds of the invention are inhibitors of alpha4 containing integrin-mediated binding to ligands such as VCAM-1 and MAdCAM.
    Type: Application
    Filed: August 21, 2009
    Publication date: December 31, 2009
    Applicant: Genentech, Inc.
    Inventors: David Y. Jackson, Frederick C. Sailes, Daniel P. Sutherlin
  • Publication number: 20090324595
    Abstract: The invention disclosed herein provides methods comprising detection of EphB2 polypeptide and/or polynucleotide in a biological sample from a subject, wherein the detection of EphB2 is predictive or indicative of cancer prognosis for the subject. The invention also provides methods for selecting cancer treatment, methods comprising detection of EphB2 polypeptide and/or polynucleotide expression in colon adenomas, and methods for treating a colon adenoma disorder. Kits, compositions, and articles of manufacture are also provided.
    Type: Application
    Filed: June 19, 2009
    Publication date: December 31, 2009
    Applicant: Genentech, Inc.
    Inventors: Adrian M. Jubb, Hartmut Koeppen
  • Publication number: 20090318409
    Abstract: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, Q, X1, X2, Y, R1, R2, R3, R4, R4?, R5, R6 and R6? are as described herein.
    Type: Application
    Filed: August 10, 2009
    Publication date: December 24, 2009
    Applicant: Genentech, Inc.
    Inventors: Frederick Cohen, Vickie Hsiao-Wei Tsui, Cuong Ly, John A. Flygare
  • Publication number: 20090317384
    Abstract: Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and CD20 antibodies to treat conditions such as cancer and immune related diseases are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies in combination with CD20 antibodies.
    Type: Application
    Filed: September 7, 2005
    Publication date: December 24, 2009
    Applicant: Genentech, Inc.
    Inventor: Avi J. Ashkenazi
  • Patent number: 7635478
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: April 15, 2002
    Date of Patent: December 22, 2009
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • Patent number: 7635749
    Abstract: Peptide ligands having affinity for IgG or for serum albumin are disclosed. Also disclosed are hybrid molecules comprising a peptide ligand domain and an active domain. The active domain may comprise any molecule having utility as a therapeutic or diagnostic agent The hybrid molecules of the invention may be prepared using any of a number techniques including production in and purification from recombinant organisms transformed or transfected with an isolated nucleic acid encoding the hybrid molecule, or by chemical synthesis of the hybrid. The hybrid molecules have utility as agents to alter the elimination half-times of active domain molecules. Elimination half-time is altered by generating a hybrid molecule of the present invention wherein the peptide ligand has binding affinity for a plasma protein.
    Type: Grant
    Filed: September 26, 2006
    Date of Patent: December 22, 2009
    Assignee: Genentech, Inc.
    Inventors: Mark S. Dennis, Henry B. Lowman, Warren L. DeLano
  • Publication number: 20090313707
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO69122, PRO204, PRO214, PRO222, PRO234, PRO265, PRO309, PRO332, PRO342, PRO356, PRO540, PRO618, PRO944, PRO994, PRO1079, PRO1110, PRO1122, PRO1138, PRO1190, PRO1272, PRO1286, PRO1295, PRO1309, PRO1316, PRO1383, PRO1384, PRO1431, PRO1434, PRO1475, PRO1481, PRO1568, PRO1573, PRO1599, PRO1604, PRO1605, PRO1693, PRO1753, PRO1755, PRO1777, PRO1788, PRO1864, PRO1925, PRO1926, PRO3566, PRO4330, PRO4423, PRO36935, PRO4977, PRO4979, PRO4980, PRO4981, PRO5801, PRO5995, PRO6001, PRO6095, PRO6182, PRO7170, PRO7171, PRO7436, PRO9912, PRO9917, PRO37337, PRO37496, PRO19646, PRO21718, PRO19820, PRO21201, PRO20026, PRO20110, PRO23203 or PRO35250 genes.
    Type: Application
    Filed: May 18, 2006
    Publication date: December 17, 2009
    Applicants: Genentech, Inc., Lexicon Pharamaceuticals, Inc.
    Inventors: Katherin E. Combs, Ling Ling Culbertson, Frederic J. de Sauvage, Zhiyong Ding, Joel Edwards, Rosemary Girgis, Allison A. B. Horner, Harald Junge, Jagath Reddy Junutula, Erin Marie Massey, Dina R. McLain, Charles Montgomery, Bobby Joe Payne, Heidi Phillips, Ni Nancy Qian, Carolina Rangel, Tracy E. W. Sevaux, Zheng-Zheng Shi, Mary Jean Sparks, Joy Anne Stala, Peter Vogel, Weilan Ye
  • Publication number: 20090311255
    Abstract: The present application describes a method of preventing an autoimmune disease in an asymptomatic human subject at risk for experiencing one or more symptoms of the autoimmune disease, by administering a CD20 antibody to the subject in an amount to prevent the subject from experiencing one or more symptoms of the autoimmune disease.
    Type: Application
    Filed: August 7, 2009
    Publication date: December 17, 2009
    Applicant: Genentech, Inc.
    Inventors: Paul G. Brunetta, Iqbal S. Grewal, Patricia A. Walicke
  • Patent number: 7632658
    Abstract: A gram-negative bacterial cell is described that is deficient in a chromosomal gene present in a wild-type such cell which gene shares at least 80% sequence identity with the native sequence of the yfcK gene and encodes an aminopeptidase. Alternatively, a gram-negative bacterial cell is deficient in a chromosomal gene present in a wild-type such cell which gene encodes an aminopeptidase that shares at least 80% sequence identity with the native sequence of aminopeptidase b2324. Either of these types of cells, when comprising a nucleic acid encoding a heterologous polypeptide, produces an N-terminal unclipped polypeptide when it is cultured and the polypeptide recovered, with virtually no N-terminal clipped polypeptide produced as an impurity. Conversely, a method is provided for cleaving an N-terminal amino acid from a polypeptide comprising contacting the polypeptide with an aminopeptidase sharing at least 80% sequence identity with the native sequence of aminopeptidase b2324.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: December 15, 2009
    Assignee: Genentech, Inc.
    Inventor: John C. Joly